Home
Search
680 Results Found

The Right Way to Address Prescription Drug Costs
Writing for STAT News, BIO’s President and CEO Jim Greenwood teamed up with Bay City Capital’s David Beier to outline for policymakers the best approach for tackling the affordability of prescription drugs. “As policy professionals from different sides of the aisle, we believe there is a right way…

BIO Comments on Objectives for U.S. Japan Trade Agreement
BIO supports the U.S. Trade Representative’s (USTR) negotiations with the Government of Japan as an opportunity to grow U.S. exports and create U.S. jobs. We would strongly urge the U.S. government to build on the recent U.S.-Mexico-Canada agreement and that the agreement comprehensively addresses…

The Administration’s Orwellian Defense of Importing Foreign Price Controls
The Trump administration is out with a new blog post defending its plan to adopt foreign price controls for medicines covered under Medicare Part B. The blog was written in the wake of growing backlash from free-market thought leaders who are challenging the administration’s draconian proposal. …

Think the Drug-Pricing debate addresses Patient Costs? Think again.
Writing for The Hill, BIO President and CEO Jim Greenwood tackled the drug pricing debate in Washington and touched on President Trump’s proposals for lowering drug prices. On the Administration’s recent International Pricing Index (IPI), which would move from a market-based payment formula for…

Another Year, Another Misleading Insurance Company Report
Once again, Blue Cross Blue Shield is out with a report attempting to stoke fear and confusion about prescription drug costs. And once again (because we’ve chronicled it before) what the major insurance company has to say is contradicted by its own pharmacy benefits manager. These drug cost…

Patient Advocates Sounding the Alarm Over Fail First
The Centers for Medicare & Medicaid Services (CMS) has reversed a long-standing policy allowing Medicare Advantage plans to impose “step therapy” requirements for physician-administered drugs – also known as Medicare Part B. More accurately described as “fail first,” this dangerous policy will…

Watchdog Report Reaffirms Concerns With Fail First
A new report by the Office of Inspector General at the U.S. Department of Health and Human Services (HHS) reaffirms concerns with a regulatory decision that undermines the health and well-being of America’s seniors. In an abrupt reversal of long-standing policy, the Centers for Medicare &…